Novo’s Oral Semaglutide Delivers Similar Weight Loss To Wegovy In Phase III
Executive Summary
A 50mg dose of oral semaglutide showed similar weight loss to the weekly injectable version that Novo already markets as Wegovy.
You may also be interested in...
Pfizer Will Struggle To Catch Novo Nordisk With Oral Obesity Treatments
Novo Nordisk reasserted its dominance in the GLP-1 agonist field this week, while Pfizer must hope that one of its two shots on goal is a success.
Wegovy Demand Busts Through Novo Nordisk’s Expanded Capacity
Novo Nordisk said it would temporarily reduce production of the lower starting dose of Wegovy even as a second contract manufacturer has come online in April.
Lilly And Novo Nordisk Shape Up For Obesity Treatment Battle Of The Heavyweights
Eli Lilly’s Mounjaro looks set to gain US approval for obesity this year and upcoming Phase III data could help it eclipse the huge success of Novo Nordisk’s Wegovy.